BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
53.30
-0.51 (-0.95%)
Apr 28, 2026, 4:00 PM EDT - Market closed
BioMarin Pharmaceutical Revenue
In the year 2025, BioMarin Pharmaceutical had annual revenue of $3.22B with 12.87% growth. BioMarin Pharmaceutical had revenue of $874.57M in the quarter ending December 31, 2025, with 17.03% growth.
Revenue (ttm)
$3.22B
Revenue Growth
+12.87%
P/S Ratio
3.20
Revenue / Employee
$1,000,079
Employees
3,221
Market Cap
10.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.22B | 367.34M | 12.87% |
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Axsome Therapeutics | 638.50M |
| Praxis Precision Medicines | 7.46M |
BMRN News
- 1 day ago - BioMarin Completes Acquisition of Amicus Therapeutics - PRNewsWire
- 1 day ago - BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET - PRNewsWire
- 7 days ago - BioMarin Announces Board Leadership Transition - PRNewsWire
- 5 weeks ago - Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
- 6 weeks ago - BioMarin stops mid-stage trials of bone disorder treatment - Reuters
- 6 weeks ago - BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 6 weeks ago - BioMarin Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - BioMarin Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026 - Transcripts